Vera Drug Scores in Closely Watched Study in Rare Kidney Disease

Vera Therapeutics reports positive results from trial of kidney disease drug

Company plans to file for FDA approval of the drug, called atacicept, but an Otsuka therapy may be a competitive threat.

Vera drug scores in closely watched study in rare kidney disease

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a competitive corner of drug research, later this year.

Vantive will invest $1B for digitally-enabled kidney care, vital

Vantive, a company that provides vital organ therapies, announced it would invest more than $1 billion over the next five years to drive innovation of digitally-enabled therapies aimed at enhancing access to care, the patient experience and patient outcomes. In addition, the company stated that its investment in research and development as well as manufacturing capacity, is aimed at accelerating the rate of innovation. Through the development of…

Vantive To Invest $1bn For Kidney Care Advancement   - Data Intelligence

Vantive came into being after Baxter divested its kidney care business to Carlyle in a $3.5bn deal last year. Image credit: Marko Aliaksandr via Shutterstock Vantive is investing $1bn towards advancing its kidney care and vital organ support proposition. The company, which was formerly Baxter’s kidney care unit, becoming Vantive after being spun out as part of a $3.5bn divestment deal with global investment firm Carlyle in 2024, stated that the …

Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data

Vera Therapeutics' share price surged over 65% during the pre-market trading session after the company released ORIGIN Phase 3 trial data.This …

Atacicept Achieves Endpoints in Phase 3 ORIGIN Trial for IgA Nephropathy

Vera Therapeutics intends to bring the results before the FDA by the end of 2025; they anticipate an approval and commercial launch in 2026.